健友股份:门冬胰岛素虽已获美国FDA批件 暂未实现首单销售

智通财经
Sep 17
【健友股份:门冬胰岛素虽已获美国FDA批件 暂未实现首单销售】健友股份在9月17日召开的2026年半年度业绩说明会上表示,阿达木单抗高浓度版本项目正常推进,但生物药审评存在不确定性。门冬胰岛素虽已获美国FDA批件,现阶段仍在备货、客户准入和订单洽谈阶段,暂未实现首单销售,美国商业化落地需要一定周期。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10